Kodiak Sciences stock up 155% after eye-drug trial wins; the data shows "as good as" the standard, not better

Kodiak Sciences shares more than doubled on Monday after the company said both of its drugs met their main goals in DAYBREAK, a Phase 3 trial in wet age-related macular degeneration, the leading eye disease it targets. The stock traded at $82.42 at 11:56 a.m. ET, up 154.8% from Friday's $32.35 close, after touching $87.83, according to Nasdaq data. Before Monday, its 52-week high was $47.84.

What the trial actually showed

According to Kodiak's release, both Zenkuda (tarcocimab tedromer) and a second drug, tabirafusp-ted, achieved "non-inferiority in vision gains compared to aflibercept at year one." Aflibercept is the long-established injected treatment; Benzinga's headline framed the result as Kodiak's drug being "on par with Regeneron's medicine."

• Zenkuda: met its primary endpoint (p-value 0.0007). 54% of patients were on six-month dosing at year one under strict retreatment rules that required another injection for any detectable fluid in the retina.
• Safety: 0% intraocular inflammation and a 0.5% cataract adverse-event rate for Zenkuda, against 0.9% for aflibercept.
• Tabirafusp-ted: met its vision endpoint (p-value 0.0036) and a key anatomical endpoint.
• Next step: Kodiak plans to file for approval of Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion, based on five Phase 3 studies.

What the headline leaves out

Non-inferior is not superior. DAYBREAK was designed to show Zenkuda is not worse than aflibercept on vision, and that is what it showed. The selling point is fewer injections, not better eyesight. Turned around, the same number that makes the headline says 46% of Zenkuda patients were not on the six-month interval at year one (our calculation from the 54%).

The second drug needs more work. Tabirafusp-ted adds an IL-6 blocker to the standard mechanism, and the idea was to do better than today's treatments. In this trial it matched, but did not beat, aflibercept. Kodiak says it will run follow-up analyses to find "which treatment naïve wAMD patient sub-groups can benefit from IL-6 inhibition," and is pursuing a superiority case in diabetic macular edema in its separate ALTO trial.

This has been a long road. Kodiak's chief medical officer said the result came "four years and seven months after our first Phase 3 readout." The company still describes itself as precommercial: it sells no approved product, and Zenkuda has not yet been submitted to regulators.

What traders are watching

At Monday's price, Nasdaq puts Kodiak's market value at about $5.2 billion. More than 23 million shares had traded by late morning, against an average of about 662,000 a day, roughly 35 times normal volume (our calculation). Nasdaq's listed one-year analyst price target, $58, now sits well below the share price, and targets typically get revised after a readout like this.

Regeneron, whose aflibercept was the comparator, was down 3.3% at $762.27 at the same time, in a market where the S&P 500 was down about 0.9%. We could not confirm how much of that move is about Kodiak's data. The next dated catalysts from Kodiak are the Zenkuda filing this quarter and the first Phase 3 readout for KSI-101, a third drug, in December 2026.

More from today's market: MongoDB falls 21% as its CEO leaves for Meta and live market data.

Sources: Kodiak Sciences press release; Investing.com via Yahoo Finance; Seeking Alpha; Benzinga; Nasdaq quote data. This is market information, not investment advice.